Neuroblastomas with discordant genotype-phenotype relationships: Report of four cases with MYCN amplification and favorable histology

Pediatric and Developmental Pathology

Volumn 14, Issue 2, 2011, Pages 87-92

  Nakagawa, Atsuko ^a   Matsuoka, Kentaro ^a   Okita, Hajime ^a   Iwafuchi, Hideto ^b   Hori, Hisanari ^b   Kumagai, Masaaki ^a  

^a NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

Author keywords

Favorable histology; MYCN amplification; Neuroblastoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; MYCN PROTEIN; PIRARUBICIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; MESSENGER RNA; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; TUMOR MARKER;

ADRENAL TUMOR; ARTICLE; CANCER DIAGNOSIS; CASE REPORT; CELL TYPE; CHILD; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; CANCER STAGING; GENETICS; GENOTYPE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHENOTYPE; RADIOTHERAPY;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; GENE AMPLIFICATION; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHENOTYPE; RADIOTHERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STEM CELL TRANSPLANTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 80054055239     PISSN: 10935266     EISSN: 16155742     Source Type: Journal    
DOI: 10.2350/08-12-0579.1     Document Type: Article

References (20)

1. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349-363. (Pubitemid 29327593)
2. Peuchmaur M, d'Amore ES, Joshi VV, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98:2274-2281. (Pubitemid 37392433)
3. Kobayashi C, Monforte-Munoz HL, Gerbing RB, et al. Enlarged and prominent nucleoli may be indicative of MYCN amplification. Cancer 2005;103:174-180.
4. Tornoczky T, Kalman E, Kajtar P, et al. Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior. Cancer 2004;100:390-397. (Pubitemid 38063650)
5. Thorner PS, Ho M, Chilton-McNeill S, Zielenska M. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections. Am J Surg Pathol 2006;30:635-642. (Pubitemid 44265016)
6. Tornoczky T, Semjen D, Shimada H, et al. Pathology of peripheral neuroblastic tumors: significance of prominent nucleoli in undifferentiated/ poorly differentiated neuroblastoma. Pathol Oncol Res 2007;13:269-275. (Pubitemid 351287306)
7. Papachristou DJ, Goodman MA, Cieply K, et al. Comparison of allelic losses in chondroblastoma and primary chondrosarcoma of bone and correlation with fluorescence in situ hybridization analysis. Hum Pathol 2006;37:890-898. (Pubitemid 43902951)
8. Gilbert J, Norris MD, Haber M, et al. Determination of N-myc gene amplification by differential polymerase chain reaction. Mol Cell Probes 1993;7:227-234. (Pubitemid 23232243)
9. Cohn SL, Tweddle DA. MYCN amplification remains prognostically strong 20 years after its "clinical debut." Eur J Cancer 2004;40: 2639-2642. (Pubitemid 39574716)
10. Tonini GP, Boni L, Pession A, et al. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J Clin Oncol 1997;15: 85-93. (Pubitemid 27020561)
11. Wenzel A, Czieplunch C, Hamann U, et al. The N-Myc oncoprotein is associated in vivo with the phosphoprotein Max(p20/22) in human neuroblastoma cells. EMBO J 1991;10:3703-3712. (Pubitemid 21905397)
12. Shimada H, Stram DO, Chatten J, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst 1995;87:1470-1476.
13. Cohn SL, Look AT, Joshi VV, et al. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group Study. Cancer Res 1995;55:721-726.
14. Goto S, Umehara S, Gerbing RB, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with periphral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001;92:2669-2708.
15. Shimada H, Nakagawa A, Peters J, et al. Trk A expression in peripheral neuroblastic tumors: prognostic significance and biological relevance. Cancer 2004;101:1873-1881. (Pubitemid 39314752)
16. George RE, Variend C, Cullinane SJ, et al. Relationship between histological features, MYCN amplification, and prognosis: a UKCCSG Study. Med Pediatr Oncol 2001;36:169-176.
17. Fabbretti G, Valenti C, Loda M, et al. N-myc gene amplification/ expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma). Hum Pathol 1993;24:294-297. (Pubitemid 23086365)
18. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group report. J Clin Oncol 2000;18:18-26. (Pubitemid 30036332)
19. Alvarado CS, London WB, Look AT, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2000;22:197-205. (Pubitemid 32268303)
20. Schneiderman J, London WB, Brodeur GM, et al. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J Clin Oncol 2008;26:913-918. (Pubitemid 351398084)